Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | JAK inhibitor combination therapy for the treatment of myelofibrosis

Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, discusses Phase III trials investigating the combination of the JAK inhibitor ruxolitinib with pelabresib (MANIFEST-2; NCT02158858) or navitoclax (TRANSFORM-1; NCT04472598) for patients with myelofibrosis (MF). The results from these trials demonstrate the superiority of this combination in reducing splenomegaly compared to ruxolitinib alone, signaling a shift from JAK inhibitor monotherapy towards combination therapy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Research Funding: Promedior, Incyte, Genetech, Abbvie, Samus, Celgene, Constellation, CTI BioPharma., a Sobi Company, Mays Cancer Center, NCI; Consultancy: Constellation,  LaJolla Pharma, Sierra Onc, Novartis.